Toni Alfaiate Selected Research

COVID-19

12/2021

An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Toni Alfaiate Research Topics

Disease

1	COVID-19 12/2021
1	Osteoarticular Tuberculosis 01/2021
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2020
1	Overweight 01/2020
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2017
1	Hypersensitivity (Allergy) 01/2017
1	Acute Coronary Syndrome 01/2017
1	Coronary Disease (Coronary Heart Disease) 01/2017
1	Ascites 04/2016
1	Fistula 04/2016
1	Rheumatoid Arthritis 01/2016
1	Necrosis 01/2016
1	Coinfection 03/2014
1	Ventilator-Associated Pneumonia 03/2014

Drug/Important Bio-Agent (IBA)

1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 12/2021
1	Lopinavir FDA Link 12/2021
1	Ritonavir (Norvir)FDA Link 12/2021
1	RubidiumIBA 01/2020
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2017
1	Tumor Necrosis Factor InhibitorsIBA 01/2016
1	Carbapenems (Carbapenem Antibiotics)IBA 03/2014
1	carbapenemaseIBA 03/2014
1	LactamsIBA 03/2014

Therapy/Procedure

1	Therapeutics 01/2021
1	Length of Stay 04/2016
1	Injections 01/2016